Acumen Pharmaceuticals (ABOS) Profit After Tax (2020 - 2026)

Acumen Pharmaceuticals' Profit After Tax history runs 7 years deep, the most recent figure standing at -$20.7 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 27.99% year-over-year to -$20.7 million; the TTM figure through Mar 2026 stood at -$113.3 million (up 2.56% YoY), while the FY2025 annual figure was -$121.3 million, down 18.57% from the prior year.
• Profit After Tax came in at -$20.7 million for Q1 2026 at Acumen Pharmaceuticals, up from -$25.1 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$9.1 million in Q1 2022 to a low of -$40.9 million in Q2 2025.
• A 5-year average of -$20.0 million and a median of -$16.5 million in 2023 frame the typical range for Profit After Tax.
• On a YoY basis, Profit After Tax climbed as much as 83.46% in 2022 and fell as far as 174.47% in 2022.
• Acumen Pharmaceuticals' Profit After Tax stood at -$12.9 million in 2022, then declined by 28.22% to -$16.5 million in 2023, then slumped by 125.22% to -$37.2 million in 2024, then surged by 32.34% to -$25.1 million in 2025, then gained by 17.51% to -$20.7 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$20.7 million, -$25.1 million, and -$26.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison